| 1.235 -0.215 (-14.83%) | 10-24 15:01 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.83 | 1-year : | 2.14 |
| Resists | First : | 1.57 | Second : | 1.83 |
| Pivot price | 1.05  |
|||
| Supports | First : | 1.02 |
Second : | 0.68 |
| MAs | MA(5) : | 1.29 |
MA(20) : | 1 |
| MA(100) : | 0.78 |
MA(250) : | 1.21 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 66.2 |
D(3) : | 70 |
| RSI | RSI(14): 60.2 |
|||
| 52-week | High : | 2.91 | Low : | 0.62 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NAUT ] has closed below upper band by 26.6%. Bollinger Bands are 386.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 17 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.48 - 1.49 | 1.49 - 1.49 |
| Low: | 1.22 - 1.23 | 1.23 - 1.24 |
| Close: | 1.44 - 1.45 | 1.45 - 1.46 |
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Fri, 24 Oct 2025
Nautilus Biotechnology Inc expected to post a loss of 15 cents a share - Earnings Preview - TradingView
Wed, 22 Oct 2025
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Insiders Have Had a Fantastic Week as Stock Increased 51%, and They Haven't Stopped Buying - 富途牛牛
Tue, 07 Oct 2025
Nautilus Biotechnology, Inc. to Announce Third Quarter 2025 Financial Results on October 28, 2025 - Quiver Quantitative
Tue, 07 Oct 2025
Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025 - GlobeNewswire
Tue, 16 Sep 2025
Favourable Signals For Nautilus Biotechnology: Numerous Insiders Acquired Stock - simplywall.st
Sat, 13 Sep 2025
Nautilus Biotechnology to Participate in Upcoming September Investor Conferences - Investing News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 126 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 33.5 (%) |
| Held by Institutions | 46.3 (%) |
| Shares Short | 188 (K) |
| Shares Short P.Month | 225 (K) |
| EPS | -0.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.42 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.3 % |
| Return on Equity (ttm) | -31.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.58 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -55 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | -2.39 |
| PEG Ratio | 0 |
| Price to Book value | 0.86 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.87 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|